“Activity Monitoring Assessment of Opiate Withdrawal — 4,” led by Dr. Steven Deutsch of the Veterans Administration, Washington, D.C., from Sept. 20, 1999, to Aug. 16, 2005, gave morphine “to determine if hyperactivity accompanies abrupt opiate withdrawal … to determine if computerized solid state activity monitors are capable of quantifying hyperactivity, and to quantify the physical and affective symptoms occurring during abrupt withdrawal. …”
Government Drug Experiments |
“Human Dopamine Transported Imaging in Cocaine Abuse: 1-1,” led by Dr. Dean Wong of Johns Hopkins University in Baltimore, from Sept. 20, 1999, until June 23, 2005, gave cocaine “to determine the density of [dopamine] transporters during prolonged cocaine abuse and during withdrawal from cocaine use.”
“Stress Hormones and Human Cocaine Use — 7,” originally led by Dorothy Hatsukami of the University of Minnesota, from Sept. 20, 1999, to Nov. 3, 2005, gave cocaine “to determine the HPA (hypothalamic-pituitary-adrenal) axis and adrenergic system activation in response to cocaine administration.”
“Development of Human Laboratory Study Model of Cocaine Relapse Prevention II — 1,” led by John Roache of the University of Texas, beginning Oct. 15, 2004, and still open, gives cocaine to “study of classical conditioning mechanisms associated with arousal, craving and cocaine use.”
“Effects of Vigabatrin on Cocaine Self-Administration,” led by Margaret Haney of the Irving Center for Clinical Research in New York, from Sept. 7, 2006 and still open — and recruiting volunteers — the study gives cocaine to “determine if (the anticonvulsant drug) Vigabatrin will decrease cocaine self-administration, cardiovascular effects, subjective effects and craving compared to placebo.”
– Source: ClinicalTrials.gov
